CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, announced today that results of the Phase 2 study of its lead compound for essential tremor will be presented as a late-breaking poster at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong October 5-9, 2018.
Cavion’s team of experts is developing oral small molecules designed to selectively modulate T-type calcium channel activity in the central nervous system, acting as a biological “pacemaker” to help restore the brain’s natural rhythms. The company’s lead compound, CX-8998, was evaluated in the T-CALM study, a Phase 2, double-blind, placebo controlled clinical trial of 95 patients with essential tremor conducted at 25 sites across the United States. Patients were randomized to receive either placebo or CX-8998 titrated up to 10mg dosed twice daily (BID). A majority of subjects (64 percent) added study drug to their existing standard of care anti-tremor medication.
“Cavion is dedicated to developing first-in-class T-type calcium channel therapies aimed at improving function for people with movement disorders and rare neurological diseases, using state-of-the-art clinical development methodologies,” said Spyros Papapetropoulos, MD, PhD, Cavion’s Executive Vice President of Research & Development and Chief Medical Officer. “Our T-CALM study is one of the largest Phase 2 essential tremor clinical trials ever conducted, and CX-8998 is the only late-stage essential tremor small molecule in development for this disease. We look forward to presenting these results as we grow the body of clinical evidence supporting our ground-breaking approach in essential tremor, a disorder that has not seen any new approved drug therapies in more than 30 years.”
The T-CALM study abstract was selected for a late-breaking poster presentation on Monday, October 8:
“Proof-of-Concept, Double-Blind, Placebo-Controlled Study for CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Antagonist in Essential Tremor Patients (T-CALM): Efficacy and Safety Results.”
|Session time: 13:15 – 14:45|
|Location: Hall 3FG|
|Abstract Number: LBA 22|
Additional Cavion research to be presented at the Congress includes:
- Proof-of-Principle Quantitative EEG Study Of CX-8998, An Oral, Potent and Selective T-Type Calcium Antagonist in Development for Symptomatic Treatment of Essential Tremor and Parkinson’s Disease Tremor
- A Phase 2 Efficacy Study of CX-8998, A Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s Disease Tremor (PDT) Patients: Design and Dose-Selection Rationale
- Therapeutic Exposures of CX-8998, A Potent, Selective and State Dependent Cav3 Channel Antagonist in Development for Essential Tremor and Parkinson’s Disease Tremor in Cav3 Driven Neurological Models
About Cavion, Inc.
Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion’s portfolio of T-type calcium channel modulators is being developed to restore the brain’s natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson’s disease tremor, neuropathic pain, and epilepsy with absence seizures.
About Essential Tremor
About 10 million Americans and 42 million people worldwide are affected by essential tremor (ET), the most common movement disorder. ET is a progressive neurodegenerative disease that ranges from mild to fully debilitating, with significant effects on people’s quality of life and activities of daily living, such as eating and drinking, dressing, writing and typing. The condition can lead to social embarrassment, phobia, anxiety, and depression. With no new drugs approved for more than three decades, there is an incredible need for new and effective options for patients with ET (Haubenberger and Hallett. 2018. Essential Tremor. New England Journal of Medicine. 378:19).
This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law.